Profile picture

Doctor Neha Pagidipati

Duke Clinical Research Institute, Durham (United States of America)
Follow
Biography
Neha J. Pagidipati, MD MPH is an Associate Professor of Medicine and cardiometabolic disease prevention specialist at the Duke Clinical Research Institute. She has been involved with cardiometabolic disease prevention research since 2011. Currently, her research focuses on clinical trials and implementation of evidence-based care of patients with high cardiovascular disease risk and lipid disorders, hypertension, diabetes, and/or obesity. Clinically, she directs the Duke Cardiometabolic Prevention Program, which focuses on behavior change and risk factor management in patients at high risk of cardiovascular and metabolic diseases.
Logo ESC

Contributor content

Therapeutic implications: can we target adipose tissue to treat HFpEF
Presentation
Therapeutic implications: can we target adipose tissue to treat HFpEF
Ask the Trialists - KARDIA-3
Presentation
Ask the Trialists - KARDIA-3
KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk
Presentation
KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk
Panel discussion.
Presentation
Panel discussion.
Exploring the gap between data and clinical practice.
Presentation
Exploring the gap between data and clinical practice.
Risk prediction for ASCVD in primary prevention patients on statin therapy
Presentation
Risk prediction for ASCVD in primary prevention patients on statin therapy
The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial
Presentation
The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial

ESC 365 is supported by